Aardvark Therapeutics, Inc. Common Stock

NASDAQ: AARD · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001774857Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

40D

FH 53DQ 21GM —SS 36

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$57.6M

Employees

Market cap

$124.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$57.6M-$57.6M2025

Operating income-$62.7M-$62.7M2025

Total assets$117.2M$117.2M2025

Liabilities$10.5M$10.5M2025

Equity$106.6M$106.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Aardvark Therapeutics, Inc. Common Stock booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Unicycive Therapeutics, Inc.31D Avita Medical Inc.50D PepGen Inc.——Spero Therapeutics, Inc.68B

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Sempra$12.4B64C Realty Income Corporation$5.7B59C ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+DexCom, Inc.$4.7B87A

Key facts

CEOTien-Li Lee

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: AARD

Employees22

IPO date2025-02-13

Latest filings

DEF 14A2026-07-10 8-K2026-06-12 8-K2026-05-14 10-Q2026-05-07 8-K2026-05-07 8-K2026-03-24 8-K2026-03-23 10-K2026-03-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.